By Market Intelligence Team

LUCID and Japan Tobacco Inc. (JT) are partnering on the development of a prescription digital therapeutic for Alzheimer’s disease. The digital therapeutic, called LUC-101, uses personalized music treatment to reduce agitation and anxiety in dementia care. JT is providing funding for LUCID to conduct research and continue developing the digital therapeutic. With LUC-101, LUCID strives to deliver the benefits of personalized music therapy for Alzheimer’s while lowering the overall cost and barrier to entry through artificial intelligence (AI) technology and cloud-enabled applications. Sheridan College’s Centre for Elder Research is also involved in the development of LUC-101 through a Natural Sciences…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!